SMARCA4 and prostate carcinoma: AU-24118 and AU-15330 are degraders targeting family VIII BD in SMARCA4/SMARCA2 and PBRM1, which are valuable tools in castration-resistant prostate cancer treatment.766,767 AU-24118 has shown promise in inducing tumor regression at therapeutic doses.766 However, long-term treatment at high doses can lead to mutations in the BD and overexpression of ATP-binding cassette subfamily B member 1 (ABCB1), which contributes to drug resistance development.766 Combining these treatments with ABCB1 inhibitors could potentially mitigate resistance to SMARCA4/SMARCA2 inhibitors in vivo.